The lead investor in the round was Big Sky Capital, an international venture fund. Most Ventures, Aloqa Ventures, Uzcard Ventures, Timur Turlov, UMAY angels and Ynta Group participated in the round. A significant part of investors accepted the condition that the valuation will be determined within 3 years, and another part accepted the valuation of $12 mln pre-money.
“Our team is delighted that investors are willing to make such a high-risk investment in Kazakhstani MedTech. As you know, we have entered Uzbekistan, work is underway on Saudi Arabia. But the main focus of the company is the United States,” said Doszhan Zhusupov, founder of CerebraAI.
CerebraAI is an artificial intelligence for timely recognition of stroke. The project raises a serious problem – stroke is one of the leading causes of mortality in Kazakhstan and the world. The innovative development of Doszhan’s team is designed to help doctors make the diagnosis as quickly and accurately as possible with the help of modern technology.
“We promise investors that we will work 3 times more than other laboratories and we are not afraid of risks with the goal of creating a new standard in emergency medicine in the world. We are fortunate that we are not alone in this mission – we have the support of Stanford and the University of Texas Health Science Center in Houston,” Doszhan Zhusupov commented on the news.
CerebraAI won the main prize of the international startup competition Innov8. The service was recognized as the best innovative project of the year. 200 projects participated in Innov8, only 6 startups were admitted to the final pitch-off after 2 rounds. The competition was held as part of the Global Health Exhibition, the largest and most prestigious medical conference in the Middle East. In addition to winning the prize money and access to the KSA Ministry of Health sandbox, the team will receive a free booth at Global Health Exhibition 2024, as well as access to the SEHA Virtual Hospital and the Innovation Assistance Center.
The CerebraAI startup was developed by Almaty A.I. Lab, which has been developing technologies in the field of artificial intelligence since 2018. To date, more than 100 thousand patients have been analyzed through the CerebraAI program, more than 500 doctors use artificial intelligence, 46 medical institutions trust and use the capabilities of CerebraAI.